Immunology is an area of growth for Sanofi Genzyme and an area in which we hope to make a significant difference in patients’ lives. In collaboration with Regeneron, we currently have one therapy on the market and are researching and developing several new therapeutic areas.
The first therapy, which is approved in the U.S., is for adults with inadequately controlled moderate-to-severe atopic dermatitis, a chronic inflammatory skin disease and the most common form of eczema. A second therapy is currently under investigation for the treatment of adults with moderate to severe rheumatoid arthritis, a chronic and painful inflammatory disorder that damages the joints.
We are also studying other allergic and respiratory diseases, including asthma, and nasal polyposis, and eosinophilic esophagitis.
Last Updated: 3/23/2017